

OCT 31 2007

Application No. 10/670,472

Amendment dated October 31, 2007

After Final Office Action of August 10, 2007

Docket No. NY-LUD 5780.2 (10312064)

AMENDMENTS TO THE CLAIMS

1. (Previously presented) An isolated peptide consisting of amino acid sequence ALKDVEERV (SEQ ID NO: 3).
- 2.-10. (Canceled)
11. (Withdrawn) A method for determining if a cell presents an HLA-A2 molecule on its surface comprising contacting a sample containing said cell with the peptide of claim 1 and determining binding there between, said binding being indicative of HLA-A2 on the surface of said cell.
- 12-26. (Canceled)
27. (Withdrawn) A method for determining if a cytolytic T cell (CTL) specific to complexes of an HLA-A2 molecule and a peptide is present in a sample, comprising admixing said sample with an HLA-A2 molecule and the peptide of claim 1 and determining a response by said CTL to complexes of HLA-A2 molecule and said peptide wherein a response by said CTL is indicative of its specificity.
28. (Previously presented) An isolated complex useful in isolating a cytolytic T cell, comprising a first and second binding partner which are specific for each other, wherein said second binding partner is bound to a plurality of tetramers of an HLA-A2 molecule, a β_2 microglobulin molecule, and the peptide of claim 1.
29. (Original) The isolated complex of claim 28, further comprising a label.
30. (Original) The isolated complex of claim 28, wherein said first binding partner is avidin and said second binding partner is biotin.

Application No. 10/670,472

Amendment dated October 31, 2007

After Final Office Action of August 10, 2007

Docket No.: NY-LUD 5780.2 (10312064)

31. (Original) A composition comprising the tetramer of claim 28 and a carrier.
32. (Canceled) A method for monitoring status of a tumor, comprising contacting a sample taken from a patient having a tumor with the isolated complex of claim 28, assaying the sample for a level of cytolytic T cell response, and comparing the response level of the cytolytic T cells in the sample to a known level of cytolytic T cell response to monitor the status of said tumor.
33. (Previously presented) A method for detecting a cytolytic T cell (CTL) specific for a complex of an HLA-A2 molecule, and an isolated peptide that consists of amino acid sequence SEQ ID NO: 3,
- (a) contacting a cytolytic T cell-containing sample with a composition comprising tetramers of an HLA-A2 molecule, β_2 microglobulin, biotin and peptide SEQ ID NO: 3,
 - (b) determining if a CTL in said CTL-containing sample recognizes said tetramers,
- wherein recognition of said tetramers is indicative of a CTL specific for a complex of the HLA-A2 molecule and said isolated peptide.
- 34-44. (Canceled)
45. (Previously presented) An isolated peptide consisting of amino acid sequence ALKDVEERA (SEQ ID NO: 5).
46. (Previously presented) A method for determining if a cell presents an HLA-A2 molecule on its surface comprising contacting a sample containing said cell with the peptide of claim 45 and determining binding there between, said binding being indicative of HLA-A2 on the surface of said cell.